Alpha Teknova (NASDAQ:TKNO) vs. Alnylam Pharmaceuticals (NASDAQ:ALNY) Financial Review

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Alpha Teknova (NASDAQ:TKNO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares Alnylam Pharmaceuticals and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	1.36%	26.61%	0.99%
Alpha Teknova	-45.78%	-23.53%	-16.16%

Insider and Institutional Ownership

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and Alpha Teknova”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25 billion	21.23	-$278.16 million	$0.24	1,505.27
Alpha Teknova	$37.74 million	4.65	-$26.75 million	($0.35)	-9.36

Alpha Teknova has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alpha Teknova is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Alnylam Pharmaceuticals and Alpha Teknova, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0	5	22	0	2.81
Alpha Teknova	1	1	1	1	2.50

Alnylam Pharmaceuticals presently has a consensus price target of $485.21, indicating a potential upside of 34.31%. Alpha Teknova has a consensus price target of $10.00, indicating a potential upside of 205.34%. Given Alpha Teknova’s higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Alnylam Pharmaceuticals.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

Summary

Alnylam Pharmaceuticals beats Alpha Teknova on 10 of the 15 factors compared between the two stocks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.